Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;13:5478. doi: 10.1038/s41467-022-33172-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Number of patients with genomic alterations at either timepoint per treatment arm. Genomic alterations include non-synonymous single-nucleotide variants (SNV), indels, and gene rearrangements. Layered above the red bar is the corresponding percentage of patients with selected alterations, defined as an increase by 25 percentage points in the normalized MAF, calculated relative the highest reported MAF, between paired baseline and end of study cfDNA from 333 1L mCRC patients treated with either bevacizumab or cetuximab in combination with chemotherapy in the CALGB/SWOG 80405 trial. Asterisks indicate statistically significant differences (FDR p-value < 0.2) by two-tailed Fisher’s exact test, restricted to 18 genes with at least 2 selected alterations in either arm. b Distribution of the % change in relative MAF between baseline and end of study for all KRAS and ARID1A alterations detected in all patients. Dashed line represents 25% threshold used to call tumors with selected mutations. c Clinical information for patients with selected ARID1A and/or KRAS alterations. d Representative mutation evolution maps for cetuximab-treated patients with selected ARID1A mutations. The maximum observed % MAF is shown at the bottom for each timepoint. PRE, at baseline; OTH, on treatment; EOT, at progression or end of study.